MSB Trading - 2020, page-6397

Prior to remestemcel - L therapy survival rates were 1 in 10 of patients on ventilators.

Although we only have a comparatively small sample size , to move survival rates from 10 % to 83% is remarkable.

Even with a larger trial of 240 patients taking a worst case scenario we are still a long way off a 10% survival rate.

Would health officials and patients be satisfied with a 75% survival rate compared to 10%?

Or even 50% from where we are now?

That is the unique position that MSB is in right now in the middle of the world's worst pandemic in 100 years.

They have a treatment which will save lives now.

The planets have aligned for MSB in this most terrible of times.

That is why I don't see any downside from here given the treatment options currently available and as many LTHs have stated shines the light on a company with a long history of development.